Silence Therapeutics PLC ADR SLN
News
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera